clinical trial · NCT06566261

ABA-101 in Participants With Progressive Multiple Sclerosis

Abata Therapeutics →·phase1·active not recruiting·n = 12

Progressive Multiple SclerosisABA-101

brief summary

This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.

started

Sep 11, 2024

primary completion

Feb 1, 2026

completion

Feb 1, 2027

last updated

Jul 3, 2025

official title

A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol